Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

September 27, 2023

Primary Completion Date

November 26, 2029

Study Completion Date

December 26, 2029

Conditions
Neuroendocrine Tumors UnresectableNeuroendocrine Tumor MetastaticGastroenteropancreatic Neuroendocrine TumorBronchial Neuroendocrine TumorParagangliomaPheochromocytoma
Interventions
DRUG

[203Pb]VMT-α-NET

\[203Pb\]VMT-α-NET is administered by intravenous bolus injection for single-photon emission computed tomography imaging.

DRUG

[212Pb]VMT-α-NET

\[212Pb\]VMT-α-NET is administered by intravenous infusion for treatment of SSTR2 expressing neuroendocrine tumors.

Trial Locations (15)

21287

RECRUITING

Johns Hopkins, Baltimore

22031

RECRUITING

Virginia Cancer Specialists, Fairfax

32224

RECRUITING

Mayo Clinic, Jacksonville

33165

RECRUITING

Biogenix Molecular, Miami

37232

RECRUITING

Vanderbilt-Ingram Cancer Center, Nashville

40536

RECRUITING

University of Kentucky, Lexington

43210

RECRUITING

Ohio State University, Columbus

48098

RECRUITING

Michigan Health Professionals, Troy

48201

RECRUITING

Barbara Ann Karmanos Cancer Institute, Detroit

49503

RECRUITING

BAMF Health, Grand Rapids

52242

RECRUITING

University of Iowa, Iowa City

55905

RECRUITING

Mayo Clinic, Rochester

60637

RECRUITING

The University of Chicago, Chicago

63110

RECRUITING

Washington University, St Louis

68130

RECRUITING

Nebraska Cancer Specialists, Omaha

Sponsors
All Listed Sponsors
lead

Perspective Therapeutics

INDUSTRY

NCT05636618 - Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter